Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Algernon Pharmaceuticals Inc. (C:AGN)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 400 - 601 WEST BROADWAY
VANCOUVER BC V5Z 4C2
Tel: N/A
Website: https://algernonpharmaceuticals.com
IR: See website
Key People
N/A    
Business Overview
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company's lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Financial Overview
For the three months ended 30 November 2023, Algernon Pharmaceuticals Inc revenues was not reported. Net loss decreased 72% to C$522K. Lower net loss reflects Share-based payments decrease of 88% to C$69K (expense), Marketing decrease of 82% to C$105K (expense), Research and development - Balancing va decrease of 53% to C$161K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.20 to -C$0.03.
Reporting Currency: Canadian Dollars
Enterprise value: $2.47M as of Nov 30, 2023
Annual revenue (TTM): $0.00M as of Nov 30, 2023
EBITDA (TTM): -$3.84M as of Nov 30, 2023
Net annual income (TTM): -$5.42M as of Nov 30, 2023
Free cash flow (TTM): -$1.84M as of Nov 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 21,640,762 as of Feb 8, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization